文献速递帕金森病与运动障碍

帕金森病患者壳核多巴胺合成、囊泡储存与代谢研究

Putamen Dopamine Synthesis, Vesicular Storage, and Metabolism in Patients With Parkinson Disease.
PubMed 文献 · Neurology · 2026-07-01

本研究基于2002至2024年的尸检壳核组织数据,比较13例帕金森病患者与20例对照者的多巴胺代谢指标,并通过动力学模型估算反应速率。结果显示患者壳核多巴胺减少约98%,DOPAL/DA比值约为对照的9倍,囊泡隔离估计降低98.5%,提示囊泡储存缺陷是帕金森病多巴胺缺乏的关键因素。

要点

  • 帕金森病患者壳核多巴胺减少约98%,DOPAL/DA比值约为对照的9倍。
  • 囊泡隔离估计降低98.5%,体内18F-DOPA PET显示放射性洗脱约增加3倍。
  • 囊泡摄取与泄漏的改变大于释放、再摄取及合成酶活性变化,提示囊泡储存缺陷为核心。

核心结论

  • 帕金森病残存多巴胺能末梢存在显著囊泡储存缺陷,囊泡多巴胺处理是壳核多巴胺缺乏的关键决定因素。

研究设计与样本

  • 更新2002至2024年院内尸检壳核组织数据,纳入13例帕金森病患者(中位年龄77岁,范围73-85岁)和20例对照(中位年龄77岁,范围35-91岁)。
  • 基于一级动力学和平衡方程的计算模型估算多巴胺合成、囊泡主动摄取与被动泄漏、胞吐释放与再摄取等反应速率,并与体内18F-DOPA PET结果比较。

主要发现

  • 帕金森病患者壳核组织多巴胺减少约98%,DOPAL/DA浓度比约为对照的9倍。
  • 应用最简动力学模型,囊泡隔离估计降低98.5%(0.073 vs 4.91 nmol/分钟)。
  • 体内18F-DOPA衍生放射性洗脱较对照约增加3倍,提示囊泡储存减弱。
  • 完整模型下,对照-帕金森病组间细胞内反应速率差异从大到小依次为:囊泡摄取≈囊泡泄漏>胞吐释放≈神经元再摄取>L-芳香族氨基酸脱羧酶活性≈酪氨酸羟化酶活性>其他反应。

临床怎么用

  • 结果提示囊泡单胺转运体介导的囊泡摄取减少和囊泡泄漏增加可能是帕金森病壳核多巴胺缺乏的关键机制,支持囊泡储存缺陷作为潜在干预靶点。

局限性

  • 反应速率估计取自已发表的点值而非拟合实验数据集,故未进行常规拟合优度回归统计。
  • 基于平衡方程计算反应速率时假设稳态条件,模型未涉及疾病发病机制多年动态变化,但可为疾病进展的进一步扩展提供平台。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Putamen dopamine depletion characterizes Parkinson disease (PD). Intraneuronal processes determining dopamine stores have not been systematically examined. This study explored relative contributions of dopamine synthesis, storage, and metabolism to control-PD differences. METHODS: We updated an intramural tabulation from 2002 to 2024 of postmortem putamen tissue contents of reactants, including the autotoxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), from patients with PD and controls. Based on computational models applying first-order kinetics and equilibrium equations, we then compared estimated rates of dopamine synthesis through tyrosine hydroxylase (TH), L-aromatic-amino-acid decarboxylase, vesicular active uptake and passive leakage, exocytotic release and reuptake, and other intraneuronal processes. Results from the modeling were compared with those from in vivo 18F-DOPA PET. RESULTS: Postmortem data were analyzed from 13 patients with PD (median age 77 years, range 73-85 years) and 20 controls (median age 77 years, range 35-91 years). There was approximately a 98% decrease in putamen tissue dopamine in PD, and the concentration ratio of DOPAL/dopamine (DA) was approximately 9 times that of control. Applying the simplest kinetic model, vesicular sequestration was estimated to be decreased by 98.5% (0.073 vs 4.91 nmol/minute). Approximately 3-fold greater in vivo "washout" of putamen 18F-DOPA-derived radioactivity compared with controls also indicated attenuated vesicular storage in PD. According to the complete model, control-PD differences in intraneuronal reaction rates were in descending order of vesicular uptake ≈ vesicular leakage > exocytotic release ≈ neuronal reuptake > L-aromatic-amino-acid decarboxylase activity ≈ TH activity > other reactions. DISCUSSION: Convergent quantitative evidence points to a substantial vesicular storage defect in residual dopaminergic terminals in PD. This finding challenges the sufficiency of nigrostriatal dopaminergic denervation alone to account for the biochemical phenotype of PD and highlights vesicular dopamine handling as a critical determinant of putamen dopamine deficiency. The reaction rate estimates were drawn from published point values rather than fitted to an experimental data set, and so conventional goodness-of-fit regression statistics were not conducted. Because of the assumption of steady-state conditions for calculating reaction rates based on equilibrium equations, the model does not address the dynamics of disease pathogenesis over years but does provide a platform for further extension to disease progression. BRIEF SUMMARY: We estimated rates of reactions involved with the synthesis, storage, release, reuptake, and metabolism of dopamine in the putamen in PD and found that the main intraneuronal functional abnormality separating PD from controls was attenuated vesicular sequestration, implicating decreased vesicular uptake through the vesicular monoamine transporter and increased vesicular leakiness as key determinants of putamen dopamine deficiency in PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Goldstein DS. Putamen Dopamine Synthesis, Vesicular Storage, and Metabolism in Patients With Parkinson Disease. Neurology. 2026. PMID: 42385115. doi:10.1212/WNL.0000000000218226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。